About: Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.93 (+1.46%)
NUVBNYSENuvation Bio Inc
Loading watchlist status…
Nuvation Bio Inc share price
NUVB price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
NUVB price performance
6,94%
5D
7,78%
1M
-22,66%
YTD
152,92%
1Y
NUVB price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NYSE rank
N/ASector Rank
N/Aquote.marketSignals